Research reveals why hearing loss is correlated with auditory signals failing to get transmitted along the auditory nerve.
The first patient has been enrolled in a study designed to evaluate the efficacy, safety, and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media.
Neuromonics is introducing what it calls an easy-to-use device to help tinnitus sufferers manage symptoms on demand. The Haven serves as a step between Neuromonics’ Oasis™ and Sanctuary™ devices.
The chirps of field crickets are a common part of the nocturnal sounds in summer and fall in Southern California.
An important finding was that study animals that did not get tinnitus showed fewer changes in their multisensory plasticity than those with tinnitus. In other words, their neurons were not hyperactive.
Researchers at the University of Colorado School of Medicine may have figured out what causes Meniere’s disease and how to attack it.
UT-Dallas researchers demonstrated that treating tinnitus using vagus nerve stimulation-tone (VNS) therapy brought significant improvement to some of the participants in a small clinical trial.
Neuromonics Inc, Westminster, Colo, manufacturer and distributor of tinnitus treatment devices, has named Eula Adams its new CEO.
Auris Medical, Basel, Switzerland, is about to start the planning phase for a clinical trial of its new tinnitus drug. Auris and the US Food and Drug Administration (FDA) have reached an agreement for the phase III trial of its new product to begin.
A 5-day “Tinnitus and Hyperacusis Therapy Masterclass” will be held on March 3 to 7 at Birkbeck College, University of London